Business Standard

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Expects to complete trials by year-end

Serum institute, coronavirus, vaccine, pharma, drugs
Premium

SII produces 1.5 billion annual dosages for polio, diphtheria, tetanus, BCG among other vaccines.

Sohini Das Mumbai
Pune's Serum Institute of India (SII) is all set to start phase-2 clinical trials of the Oxford University prime vaccine candidate (AZD-1222) developed in collaboration with British-Swedish pharma giant AstraZeneca. The institute expects to complete both, phase-2 and 3 trials in India by the end of this year. 

"This is because large-scale trials on over 10,000 healthy volunteers is being conducted by Oxford University in the UK and the primary data would be made available to the Indian regulator for review," said someone close to the development. By November, one can expect some conclusive data to be out, the person

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 18 2020 | 6:11 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com